Format

Send to

Choose Destination
Neuron. 2014 Nov 5;84(3):554-63. doi: 10.1016/j.neuron.2014.10.027. Epub 2014 Nov 5.

Medicines for the mind: policy-based "pull" incentives for creating breakthrough CNS drugs.

Author information

1
Department of Neurology and Neurosciences Institute, SUNY Stony Brook, Stony Brook, NY 11794, USA; Brain Science Institute, Korea Institute for Science and Technology, Seoul 136-791, Korea. Electronic address: dennis.choi@stonybrookmedicine.edu.
2
Eli Lilly and Company, Indianapolis, IN 46285, USA.
3
National Institute of Mental Health, NIH, Bethesda, MD 20892, USA.
4
National Multiple Sclerosis Society, 1100 New York Avenue NW, Washington, DC 20005, USA.
5
School of Law, Harvard University, Cambridge, MA 02138, USA.
6
Broad Institute, MIT and Harvard University, 75 Ames Street, Cambridge, MA 02142, USA.
7
Verity BioConsulting, 4711 Hope Valley Road, Durham, NC 27707, USA.
8
Voyager Therapeutics, 75 Sidney Street, Cambridge, MA 02139, USA.
9
Sloan School of Management, MIT, 50 Memorial Drive, Cambridge, MA 02142, USA.
10
The Michael J. Fox Foundation for Parkinson's Research, P.O. Box 4777, New York, NY 10163, USA.

Abstract

Several large pharmaceutical companies have selectively downsized their neuroscience research divisions, reflecting a growing view that developing drugs to treat brain diseases is more difficult and often more time-consuming and expensive than developing drugs for other therapeutic areas, and thus represents a weak area for investment. These withdrawals reduce global neuroscience translational capabilities and pose a serious challenge to society's interests in ameliorating the impact of nervous system diseases. While the path forward ultimately lies in improving understandings of disease mechanisms, many promising therapeutic approaches have already been identified, and rebalancing the underlying risk/reward calculus could help keep companies engaged in making CNS drugs. One way to do this that would not require upfront funding is to change the policies that regulate market returns for the most-needed breakthrough drugs. The broader neuroscience community including clinicians and patients should convene to develop and advocate for such policy changes.

PMID:
25442934
DOI:
10.1016/j.neuron.2014.10.027
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center